VAXIN LAUNCHES JOINT VENTURE WITH ANC BIO IN KOREA
Novartis completes shipment of US supply of Fluvirin
KIMBERLY-CLARK ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE I-FLOW CORPORATION
To keep up to date with news from this category use our
Nabi Biopharmaceuticals Completes Sale of PentaStaph(TM) to GlaxoSmithKline PLC
ROCKVILLE, Md., November 4, 2009 -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced that it has completed the sale of PentaStaph(TM) (Pentavalent S. aureus Vaccine) and related assets to GlaxoSmithKline PLC (GSK). The...
Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009
CAMBRIDGE, Mass.-- November 3, 2009-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presents preclinical data on the mechanism by which IMO-2125 was shown to induce immune activation through Toll-like Receptor 9...
Idenix Pharmaceuticals Initiates Phase II Clinical Trial of IDX184 in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
CAMBRIDGE, Mass., November 3, 2009 -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, announced today...
ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care
Tuesday 3 November 2009 -- Today, ViiV Healthcare, a new specialist HIV company established by GlaxoSmithKline (GSK) and Pfizer, was officially launched. Dr Dominique Limet, the Chief Executive Officer of ViiV...
Novavax Reports Positive Data for its Trivalent Seasonal Influenza (VLP) Vaccine Candidate in a Second Phase II Study
ROCKVILLE, MD (November 2, 2009) - Novavax, Inc. (NASDAQ: NVAX) a clinical-stage vaccine company, announced today that the Company made a poster presentation on the "Safety and Immunogenicity of a Recombinant Trivalent...
Additional Data from Fidaxomicins Phase 3 Study for Clostridium difficile infection (CDI) Presented at IDSA Annual Meeting
SAN DIEGO- October 31, 2009 - Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious...
Cancer trials and good manufacturing practice
October 30, 2009--An article in Friday's issue of the Danish medical journal 'Dagens Medicin' accuses the Danish Medicines Agency of delaying the development of new cancer medicine. The specific case involves an...
Pandemic (H1N1) 2009 Influenza Update: Experience of GSK's H1N1 adjuvanted vaccine, Pandemrix(TM), and preliminary paediatric results
October 23, 2009 -- GlaxoSmithKline (GSK) today announced that, to date, more than 150,000 people have received GSK's pandemic H1N1 vaccine, Pandemrix(TM), as part of Government initiated vaccination programmes across...
BioServe Selected by Government of A.P. India to Test H1N1 (Swine Flu) Patients
Beltsville, MD; and Hyderbad, AP, India, October 21, 2009 - BioServe(TM), a leading provider of clinical bio-samples and research services, today announced that it has been selected by the Government of the State of...
Crucell HIV Vaccine: Promising Preliminary Results Phase I Study Presented by Dr Dan Barouch at AIDS Vaccine 2009 in Paris
Leiden, The Netherlands (October 21, 2009) - Dutch biopharma company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced that preliminary results of the Phase I study of its HIV vaccine were...
Two new appointments to BioAlliance Pharma's Supervisory Board in phase with the company's development
Paris, October 21, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the appointment of two new Board members.
Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis(TM) HIV Program at the AIDS Vaccine 2009 Conference
Durham, NC and Paris, France- October 21, 2009 -- Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing...
Novavax and Xcellerex Announce Collaboration to Develop Large-scale Manufacturing Process for 2009 H1N1 Influenza VLP Vaccine
Rockville, MD and Marlborough, MA - October 21, 2009 - Novavax, Inc. (NASDAQ: NVAX) and Xcellerex, Inc. has entered into a strategic collaboration to accelerate the development of Novavax's vaccine manufacturing process...
VAXIN LAUNCHES JOINT VENTURE WITH ANC BIO IN KOREA
Birmingham, Alabama - October 14, 2009 - Vaxin Inc., an emerging vaccine company today announced that it has entered into a joint venture with South Korean biomedical company, AnC Bio Group to develop, manufacture and...
BioAlliance Pharma announces Phase I trial for Fentanyl Lauriad
Paris, October 12, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency...
Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
Rockville, Md. - October 12, 2009--- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it...
MedaSorb Technologies Corporation Raises $1.3M in Series B Warrant Exercise
MONMOUTH JUNCTION, NJ-- 10/09/09 - MedaSorb Technologies Corporation (OTC.BB:MSBT - News) and its wholly-owned subsidiary CytoSorbents, Inc., announced that it has raised $1.3 million in the exercise of the warrant...
KIMBERLY-CLARK ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE I-FLOW CORPORATION
DALLAS and LAKE FOREST, Calif., October 9, 2009 - Kimberly-Clark Corporation (NYSE: KMB) and I-Flow Corporation (NASDAQ: IFLO), a leading healthcare company that develops and markets technically advanced, low-cost drug...
TB Alliance Briefs Members of Congress on the Need for Greater U.S. Investment in TB Research
On October 8, 2009, the TB Alliance and Research!America co-sponsored a Capitol Hill Briefing in the US Senate chambers entitled, "Eliminating TB through Global Health Research" to highlight the importance and impact of...
Novartis gains exclusive worldwide rights to PTK 0796, in Phase III study as potential first-in-class IV and oral broad-spectrum antibiotic
Basel, October 8, 2009 - Novartis has gained exclusive worldwide rights to market PTK 0796, potentially the first once-daily broad-spectrum antibiotic that can be given by intravenous (IV) infusion or oral tablet to...
Panenza
Lyon, France - October 8, 2009 - Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that a single dose of influenza A (H1N1) 2009 monovalent vaccines, Panenza
NextPharma Technologies Expands its Capabilities through the Addition of Clinical Trial Services in the United States
Surrey, UK, 8th October 2009 Surrey, UK, 8th October 2009 - NextPharma, a leading service provider of product development, contract manufacturing, cold chain storage and logistics to the pharmaceutical and biotechnology...
Nutra Pharma Announces Nyloxin Rx, a Prescription Analgesic for the Treatment of Severe (Stage 3) Chronic Pain
October 07, 2009 -- Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription...
NextPharma Technologies Partners with CARBOGEN AMCIS in Alliance which combines Investigational Medicinal Product und Active Pharmaceutical Ingredient Services for Highly Potent Active Pharmaceutical Ingredients
Surrey, UK, 7th October 2009 Surrey, UK, 7th October, 2009 - NextPharma, the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the...
Amarillo Biosciences (AMAR) Partners With Intas Pharmaceuticals to Treat Influenza in India
AMARILLO, TX--(October 07, 2009) - Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Limited (Intas), one of the top 20...
Idera Pharmaceuticals Initiates Phase 1 Clinical Trial of IMO-2125, a TLR9 Agonist, in Combination with Ribavirin for Chronic Hepatitis C Virus Infection
CAMBRIDGE, Mass.-- October 7, 2009-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that patient treatment has been initiated in a phase 1 clinical trial evaluating IMO-2125 in combination with ribavirin in...
FDA Marks 100th HIV/AIDS Drug Authorized for Purchase Under PEPFAR
October 6, 2009 -- The U.S. Department of Health and Human Services (HHS) today marked today marked the recent approval of the 100th antiretroviral drug in association with the President's Emergency Plan for AIDS Relief...
Cerner Clients Connect to Fight Spread of Influenza
KANSAS CITY, Mo.-- Oct. 6, 2009 -- The U.S. Department of Health and Human Services (HHS) and the Centers for Disease Control (CDC) are collaborating with Cerner to create the Flu Pandemic Initiative, a secure,...
Novartis completes shipment of US supply of Fluvirin
Basel, October 6, 2009 - Novartis announced today that the company has completed its entire shipment of seasonal influenza vaccine to the United States for the 2009/2010 season. As previously anticipated, the company...
Cold Spring Harbor Laboratory receives more than $22 million in federal stimulus grants
Cold Spring Harbor, NY -October 6, 2009 Cold Spring Harbor Laboratory (CSHL) has been awarded more than $22 million in grants by the National Institutes of Health (NIH) and the National Science Foundation (NSF) under...
Inovio Biomedical Therapeutic Cervical Cancer Vaccine Demonstrates Safety and Immunogenicity in Clinical Trial
SAN DIEGO---Oct. 5, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic cervical...
Inovio Biomedical Therapeutic Cervical Cancer Vaccine Demonstrates Safety and Immunogenicity in Clinical Trial
SAN DIEGO-- October 5, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic...
Sequella Receives American Recovery and Reinvestment Funding through the NIH
Rockville, Md. - October 5, 2009- Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a...
Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
SAN DIEGO, October 5, 2009 -- Conatus Pharmaceuticals Inc., a privately held, clinical stage company developing a treatment for liver disease associated with Hepatitis C Virus (HCV), announced today that Steven J....
Baxter Receives EMEA Positive Opinion for CELVAPAN H1N1 Pandemic Influenza Vaccine
DEERFIELD, Ill., October 2, 2009 -- Baxter International Inc. (NYSE: BAX) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) granted its "positive...
Sanofi Pasteur and the Alliance for Rabies Control enter into a Global Partnership
Lyon, France - October 2, 2009 - Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE : SNY), and the Alliance for Rabies Control (ARC) announced today their global partnership agreement...
U.S. Navy to Fund Vical's H1N1 Pandemic Influenza (Swine Flu) Vaccine
SAN DIEGO, Oct. 1, 2009 -- Vical Incorporated (Nasdaq:VICL) announced today that the U.S. Navy has awarded a contract for $1.25 million to support large-scale cGMP vaccine manufacturing and related clinical and...
Novexatin
October 01, 2009 -- NovaBiotics announces that the phase IIa component of its first-in-man clinical trial to assess the safety, tolerability and pharmacodynamics of its topical fungal nail infection treatment, Novexatin
$1.6 Million NIH Cooperative Agreement Supports SIGA Broad Spectrum Antiviral Research
NEW YORK, Sep 29, 2009 -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced the receipt of a $1.6 million research...
Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
RICHMOND, Calif., Sept 23, 2009 -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to...
Foundation of Savira Pharmaceuticals
Vienna, 23.9.2009 - Savira, an Austrian pharmaceutical company focusing on the development of novel anti-influenza drugs was recently established in Vienna and supported with seed financing of 1 Mio Euro by the AWS...
Mylan's Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets
PITTSBURGH, September 16, 2009 -- Mylan Inc. (NASDAQ: MYL) today announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug...
ST-246 Used to Treat Complications From Exposure to Recombinant Vaccinia Virus
NEW YORK, Sep 15, 2009 -- SIGA Technologies Inc. (Nasdaq:SIGA) announced that its smallpox antiviral drug, ST-246, has been used to treat a Pennsylvania patient suffering from complications due to exposure to a live...
iBio Completes $3 Million Private Placement
NEWARK, DE - September 10, 2009 - iBio, Inc. (OTCBB: IBPM) today announced a private placement of approximately $3 million of its common stock principally to current stockholders who previously purchased the Company's...
New Test Complements Company's Broad Menu of Solutions for Surveillance of Swine Flu Infections used by Health Authorities Worldwide
Venlo, The Netherlands / Dalian, China - September 10, 2009 - QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA), today announced both the launch of a new Influenza A/H1N1 test and several updates to its activities...
Hovione's TwinCaps
Loures, Portugal, 8th September, 2009. Hovione is pleased to announce that its TwinCaps
Vical Receives Broad U.S. Patent for Vaxfectin(R)-Formulated DNA Vaccines for Influenza; Coverage Includes All Seasonal and Pandemic Strains
SAN DIEGO, Sept. 3, 2009-- Vical Incorporated (Nasdaq:VICL) announced today the issuance of U.S. Patent No. 7,582,613 covering Vaxfectin(R)-formulated DNA vaccines for influenza. The patent provides broad coverage for...
Tarix Pharmaceuticals receives IND to treat HIV patients with persistently low CD4 counts
Brookline, MA, March 21, 2008 -- Tarix Phamaceuticals announced that it has received an approval of an IND to begin a Phase Ia dose escalation study to evaluate the safety of TXA127 in HIV patients maintained on HAART...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
